Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial
This study was designed to determine the therapeutic efficacy and safety of the Shi-cha capsule, a Chinese herbal formula, in the treatment of patients with wind-cold type common cold. In our multi-center, prospective, double-blind, randomized, placebo-controlled, dose-escalation trial, patients wit...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Evidence-Based Complementary and Alternative Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/254571 |
id |
doaj-f9914ade48994b4e9211a9bb8d346456 |
---|---|
record_format |
Article |
spelling |
doaj-f9914ade48994b4e9211a9bb8d3464562020-11-24T22:29:13ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882012-01-01201210.1155/2012/254571254571Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation TrialJing Chang0Shou-Jin Dong1Bin She2Rui-Ming Zhang3Mao-Bin Meng4Yan-Ling Xu5Li-Ling Wan6Ke-Hua Shi7Jun-Hun Pan8Bing Mao9Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, West China School of Medicine, Sichuan University, 37 Guoxue Lane, Sichuan Province, Chengdu 610041, ChinaPneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, West China School of Medicine, Sichuan University, 37 Guoxue Lane, Sichuan Province, Chengdu 610041, ChinaPneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, West China School of Medicine, Sichuan University, 37 Guoxue Lane, Sichuan Province, Chengdu 610041, ChinaDivision of Clinical Pharmacology, West China Hospital, West China School of Medicine, Sichuan University, 37 Guoxue Lane, Sichuan Province, Chengdu 610041, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, ChinaDepartment of Respiratory Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, ChinaDepartment of Respiratory Medicine, Affiliated Hospital of Jiangxi College of Traditional Chinese Medicine, Nanchang 330006, ChinaDepartment of Respiratory Medicine, Shanghai Traditional Chinese Medicine Hospital, Shanghai 200071, ChinaDepartment of Respiratory Medicine, The First Affiliation Hospital of Guangzhou Medical University, Guangzhou 510405, ChinaPneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, West China School of Medicine, Sichuan University, 37 Guoxue Lane, Sichuan Province, Chengdu 610041, ChinaThis study was designed to determine the therapeutic efficacy and safety of the Shi-cha capsule, a Chinese herbal formula, in the treatment of patients with wind-cold type common cold. In our multi-center, prospective, double-blind, randomized, placebo-controlled, dose-escalation trial, patients with wind-cold type common cold received 0.6 g of Shi-cha capsule plus 0.6 g placebo (group A), 1.2 g of Shi-cha capsule (group B), or 1.2 g placebo (group C), three times daily for 3 days and followed up to 10 days. The primary end point was all symptom duration. The secondary end points were main symptom duration, minor symptom duration, the changes in cumulative symptom score, main symptom score, and minor symptom score 4 days after the treatment, as well as adverse events. A total of 377 patients were recruited and 360 met the inclusive criteria; 120 patients constituted each treatment group. Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant. There were no differences in adverse events. The Shi-cha capsule is efficacious and safe for the treatment of patients with wind-cold type common cold. Larger trials are required to fully assess the benefits and safety of this treatment for common cold.http://dx.doi.org/10.1155/2012/254571 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jing Chang Shou-Jin Dong Bin She Rui-Ming Zhang Mao-Bin Meng Yan-Ling Xu Li-Ling Wan Ke-Hua Shi Jun-Hun Pan Bing Mao |
spellingShingle |
Jing Chang Shou-Jin Dong Bin She Rui-Ming Zhang Mao-Bin Meng Yan-Ling Xu Li-Ling Wan Ke-Hua Shi Jun-Hun Pan Bing Mao Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial Evidence-Based Complementary and Alternative Medicine |
author_facet |
Jing Chang Shou-Jin Dong Bin She Rui-Ming Zhang Mao-Bin Meng Yan-Ling Xu Li-Ling Wan Ke-Hua Shi Jun-Hun Pan Bing Mao |
author_sort |
Jing Chang |
title |
Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial |
title_short |
Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial |
title_full |
Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial |
title_fullStr |
Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial |
title_full_unstemmed |
Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial |
title_sort |
treatment of common cold patients with the shi-cha capsule: a multicenter, double-blind, randomized, placebo-controlled, dose-escalation trial |
publisher |
Hindawi Limited |
series |
Evidence-Based Complementary and Alternative Medicine |
issn |
1741-427X 1741-4288 |
publishDate |
2012-01-01 |
description |
This study was designed to determine the therapeutic efficacy and safety of the Shi-cha capsule, a Chinese herbal formula, in the treatment of patients with wind-cold type common cold. In our multi-center, prospective, double-blind, randomized, placebo-controlled, dose-escalation trial, patients with wind-cold type common cold received 0.6 g of Shi-cha capsule plus 0.6 g placebo (group A), 1.2 g of Shi-cha capsule (group B), or 1.2 g placebo (group C), three times daily for 3 days and followed up to 10 days. The primary end point was all symptom duration. The secondary end points were main symptom duration, minor symptom duration, the changes in cumulative symptom score, main symptom score, and minor symptom score 4 days after the treatment, as well as adverse events. A total of 377 patients were recruited and 360 met the inclusive criteria; 120 patients constituted each treatment group. Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant. There were no differences in adverse events. The Shi-cha capsule is efficacious and safe for the treatment of patients with wind-cold type common cold. Larger trials are required to fully assess the benefits and safety of this treatment for common cold. |
url |
http://dx.doi.org/10.1155/2012/254571 |
work_keys_str_mv |
AT jingchang treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT shoujindong treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT binshe treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT ruimingzhang treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT maobinmeng treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT yanlingxu treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT lilingwan treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT kehuashi treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT junhunpan treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial AT bingmao treatmentofcommoncoldpatientswiththeshichacapsuleamulticenterdoubleblindrandomizedplacebocontrolleddoseescalationtrial |
_version_ |
1725744432620240896 |